neoadjuvant


Also found in: Dictionary, Encyclopedia, Wikipedia.

ne·o·ad·ju·vant

(nē'ō-ad'jū-vănt),
Chemotherapy or radiation given before cancer surgery.
[neo- + adjuvant]

neoadjuvant

/neo·ad·ju·vant/ (ne″o-aj´oo-vant) referring to preliminary cancer therapy, usually chemotherapy or radiation therapy, that precedes a necessary second modality of treatment.

ne·o·ad·ju·vant

(nē'ō-ad'jū-vănt)
Chemotherapy or radiation given before cancer surgery or other phase of treatment.
References in periodicals archive ?
16] Notably, neoadjuvant chemotherapy significantly increases the R0 resection rate [17] and does not influence perioperative outcomes.
Patients who respond to neoadjuvant chemotherapy have better outcomes than those who do not, so determining early in treatment who is going to be more likely to have a complete response is important," said Dawn Hershman, the co-leader of the study.
Surgery (breast and sentinel node or axillary lymph node resection) was complete three to seven weeks after the last dose of either ABP 980 or trastuzumab in the neoadjuvant phase, and pathologic complete response was analysed.
Neoadjuvant chemotherapy has become an integral part in the management of locally advanced breast cancer.
Conclusion: Molecular subtypes of breast cancer were found to be statistically significant predictor of PCR after neoadjuvant chemotherapy.
Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy.
BAVENCIO (avelumab) is a human programmed death ligand-1 (PD-L1) blocking antibody indicated in the US for locally advanced or metastatic urothelial carcinoma who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, concluded the companies.
Based on data from multiple randomized controlled trials, neoadjuvant chemotherapy (NACT) is being used more frequently.
Neoadjuvant radiotherapy (with or without chemotherapy) has been applied in advanced rectal cancer to achieve down staging, en-bloc resection, tumor shrinkage, and decreasing the rate of local recurrence.
Among 594 women with advanced ovarian cancer treated at one of six major comprehensive cancer centers, median overall survival (OS) for women with stage IIIC cancers treated with neoadjuvant chemotherapy (NACT) was 33 months, compared with 43 months for women treated with primary cytoreductive surgery (PCS), reported Larissa A.